Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treosulfan versus busulfan conditioning before allogeneic HSCT in children with non-malignant diseases
2013-005508-33Phase 2Completed
- Sponsor
- medac GmbH
- Start
- Jun 2014
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of treosulfan and busulfan in Immunogenetic disorder, Congenital Metabolic Diseases, hemoglobinopathies and 1 more (2 arms), sponsored by medac GmbH. Primary endpoint: Freedom from transplant-related mortality. Started Jun 2014; status: completed.
02
Drugs
treosulfanbusulfan
03
Conditions
Immunogenetic disorderCongenital Metabolic Diseaseshemoglobinopathiesbone marrow failure
Beyond the preview
Go deeper on 2013-005508-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005508-33.